Thrombosis News and Research

Latest Thrombosis News and Research

Results of Nordic-Baltic Bifurcation IV trial presented at TCT 2013

A new clinical trial shows that a two-stent technique for treatment of bifurcation lesions with a large stenotic side branch was not associated with significant improved outcomes compared to a provisional stenting approach.

31 Oct 2013

New strategy for emergency anticoagulant treatment for patients with myocardial infarction

A new strategy for emergency anticoagulant treatment for patients with acute myocardial infarction has been put in place by a team led by Philippe-Gabriel Steg at Inserm Unit 698 (Haemostasis, Bioengineering, Immunopathology and Cardiovascular Remodelling), at H-pital Bichat, AP-HP, Universit- Paris Diderot).

31 Oct 2013

MRSA musculoskeletal infections increasing among children

Pediatric musculoskeletal Staphylococcus aureus bacterial infections have been evolving over the past decade, with more children diagnosed with the more virulent, methicillin-resistant Staphylococcus aureus today than 10 years ago.

28 Oct 2013

Kaiser Permanente researchers named co-recipients of Drug Therapy Research Literature Award

Three Kaiser Permanente Colorado researchers have been named co-recipients of the prestigious Drug Therapy Research Literature Award, an award presented annually by the American Society of Health-System Pharmacists Foundation.

24 Oct 2013

Skin cancer drug shows periocular promise

Early research suggests that patients with periocular basal cell carcinoma may benefit from treatment with a drug targeting the Hedgehog signaling pathway.

21 Oct 2013

Ariad Ends Phase III Leukemia Drug Trial

...

18 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

Detecting dangerous blood clots in the form of simple urine test

Detecting dangerous blood clots, which can cause life-threatening conditions such as strokes and heart attacks, leading causes of death for men and women in the U.S., has been a coveted and elusive goal.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Simple urine test uses nanotechnology to detect dangerous blood clotting

Life-threatening blood clots can form in anyone who sits on a plane for a long time, is confined to bed while recovering from surgery, or takes certain medications.

17 Oct 2013

Sexual dysfunction ‘ignored in COPD’

Researchers say that physicians should address sexual issues in patients with chronic obstructive pulmonary disease as a matter of course, after finding that over three-quarters of men with the condition have some level of erectile dysfunction.

15 Oct 2013

Six-month surgery delay ‘acceptable’ after DES implantation

The recommendation to delay noncardiac surgery for a year after receipt of a drug-eluting stent, compared with just 6 weeks for a bare-metal stent, may be too conservative, suggests research indicating that stent type does not influence the longer term risk for major adverse cardiac events.

14 Oct 2013

Scientists introduce new approach to the production of synthetic heparin mimetics

One of the risks of any large operation is the occurrence of blood clots. To prevent this, patients are routinely given the anticoagulant heparin or related drugs. American scientists have now introduced a new approach to the production of synthetic heparin mimetics with better activity profiles.

11 Oct 2013

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

ARIAD Pharmaceuticals, Inc. today announced results of its review of updated clinical data from the pivotal PACE trial of Iclusig® (ponatinib) and actions that it is taking following consultations with the U.S. Food and Drug Administration (FDA).

9 Oct 2013

Understanding the biological players in clot formation could lead to new thrombotic therapies

Ulhas Naik, professor of biological sciences and director of the Delaware Cardiovascular Research Center, pores over laboratory data on his computer, even during breakfast most mornings. He is on a quest to tease out the roles that various blood components play in the formation of clots.

9 Oct 2013

Noncardiac surgery after recent coronary stent linked with increased risk of adverse cardiac events

Emergency surgery and advanced cardiac disease are risk factors for major adverse cardiac events (MACE) after noncardiac surgery in patients with recent coronary stent implantation, according to a study published by JAMA.

8 Oct 2013

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

The oral hormone therapy conjugated equine estrogens, which is used by women to relieve menopause symptoms, appears to be associated with increased risk for venous thrombosis (VT, blood clots) and possibly myocardial infarction (heart attack), but not ischemic stroke risk, when compared with the hormone therapy oral estradiol, according to a study published by JAMA Internal Medicine, a JAMA Network publication.

1 Oct 2013

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

Haemtech Biopharma Services (HBS) is pleased to announce the successful validation of a thrombin generation assay (TGA) for an IVIG drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals Corporation's U.S. Food and Drug Administration Biologics License Application for BIVIGAM® [Immune Globulin Intravenous (Human), 10% Liquid] product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram® platform (CAT) from Diagnostica Stago, Inc. (Parsippany, NJ).

1 Oct 2013

GSK Sells Thrombosis Brands To Aspen For $1.13B

...

30 Sep 2013

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application to the U.S. Food and Drug Administration for Zalviso (sufentanil sublingual microtablet system).

30 Sep 2013

Thrombosis News and Research

Latest Thrombosis News and Research

Results of Nordic-Baltic Bifurcation IV trial presented at TCT 2013

New strategy for emergency anticoagulant treatment for patients with myocardial infarction

MRSA musculoskeletal infections increasing among children

Kaiser Permanente researchers named co-recipients of Drug Therapy Research Literature Award

Skin cancer drug shows periocular promise

Ariad Ends Phase III Leukemia Drug Trial

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

Detecting dangerous blood clots in the form of simple urine test

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Simple urine test uses nanotechnology to detect dangerous blood clotting

Sexual dysfunction ‘ignored in COPD’

Six-month surgery delay ‘acceptable’ after DES implantation

Scientists introduce new approach to the production of synthetic heparin mimetics

ARIAD announces changes in Iclusig product labeling to reflect updated safety information

Understanding the biological players in clot formation could lead to new thrombotic therapies

Noncardiac surgery after recent coronary stent linked with increased risk of adverse cardiac events

Researchers compare cardiovascular safety of two commonly used oral estrogen medications

Validation of thrombin generation assay (TGA) for an IVIG drug announced by Haemtech Biopharma Services

GSK Sells Thrombosis Brands To Aspen For $1.13B

AcelRx Pharmaceuticals submits Zalviso NDA to FDA

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Thrombosis News and Research

Latest Thrombosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in